BioMarin Pharmaceuticals
BMRN
BMRN
575 hedge funds and large institutions have $18.9B invested in BioMarin Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 87 funds opening new positions, 198 increasing their positions, 202 reducing their positions, and 48 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
575
Holders Change
+28
Holders Change %
+5.12%
% of All Funds
9.28%
Holding in Top 10
15
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+15.38%
% of All Funds
0.24%
New
87
Increased
198
Reduced
202
Closed
48
Calls
$185M
Puts
$117M
Net Calls
+$68.2M
Net Calls Change
+$35.2M
Top Buyers
| 1 |
Invesco
Atlanta,
Georgia
|
+$148M |
| 2 |
CG
Carmignac Gestion
Paris,
France
|
+$89.9M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
+$73.9M |
| 4 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$73.5M |
| 5 |
Bank of New York Mellon
New York
|
+$57.7M |
Top Sellers
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$452M |
| 2 |
Millennium Management
New York
|
-$113M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$108M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$90.2M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$83.4M |
